Nvidia Looking Vulnerable To Start A More Important CorrectionWill this important momentum breakdown mark the top for Nvidia (and possibly Nasdaq and Bitcoin)? The start of a simple correction OR a vicious bear market? Let me know what you think. #nvidia #nasdaq #bitcoin #recession #unemploymentby Badcharts8
My levels to manage risks to bottom fishing $COINCoinbase's competitors: 1. Robinhood (HOOD) 2. Cash App (SQ) 3. Venmo (PYPL) Barclays bank revised its stance on Coinbase on Friday, shifting its price target down to $169 from $206 but upgrading the company to “Equal Weight” from “Underweight.”.by KhanhC.Hoang0
$QCOM - At critical supportNASDAQ:QCOM I posted on August 27 that Qualcomm might be forming a head and shoulders pattern. Look at it now. The right shoulder looks complete. It is currently sitting on critical neckline support. Remember, a head and shoulders pattern only validates if the price breaks below the neckline with multiple trading sessions closing below it. So, the pattern's validity still remains to be seen. As always, I share my opinions and trades. I'm not suggesting anyone follow my trades. You do you.by PaperBozz2
Palantir Bullish Long-Term PlayPalantir shares rose to a yearly high near $33 in the evening trading session on Friday, September 6, after announcement Palantir joins the S&P 500 index. Palantir was one of the strongest contenders for inclusion in the broad market S&P500 index. This inclusion, as well as Dell (DELL), comes after tech companies Super Micro (SMCI) and Crowdstrike (CRWD) also joined the index earlier this year. Technical 1-month graph indicates on Reversed Head-and-Shoulders structure in development. Potentially it can bring Palantir stocks, up to $100 per share over the next several years. by PandorraUpdated 6
Oracle Liquidation - Short or Sell | Yellowstone Bubble Anyone?Awhile back I posted a chart, where I referred to this current market as the "Yellowstone Bubble". Lol at the time, I was simply teasing about how ever since roughly season 4 of the show Yellowstone , it seems like everyone thinks they are some kind of tough-guy money-making, all-powerful market wizard. Google: "Yellowstone Oracle". Anyway, there's not much else to say here. The internet is a commodity.Shortby ChiefMacro1
Nvidia Go Bye Bye | Short or Take Profits Whenever news commentators feel the need to interview a CEO, and hail the CEO as some kind of benevolent "hero of the people", that is a pretty good indicator that something is awry. The same applies for rampant social media hype. At the end of the day, the chart & the macro backdrop tell the real story. NASDAQ:NVDA will collapse from here. Don't bother trying to buy any time soon, you will only be hurting yourself; this thing, along with the broader market has some significant adjusting (downward) to work through. Shortby ChiefMacro4
Long BROS @39.47 (oversold)Just went long bc I missed it at the close yesterday. Oversold and will hold each lot until overbought and profitable, adding lots as long as it's oversold. Record over the last 12 months for indicator and exit strategy on BROS: 40-0 Avg gain = 5.8% Median gain = 4.2% Range = +0.1% to 18.2% Cumulative 12M gain on equal dollar amount trades: 232% A weird one to trade. 12 of the wins gained less than 1% and 11 were over 10%. Last 7 trades were all +10% or more. This one can have very long losing streaks, though. Held as many as 17 lots at once before closing bc of a long downtrend. It's a great reminder to use position sizes that keep you from running out of capital before the stock runs out of downward momentum. This one gives trading opportunities really often, too. 40 in 12 months is a LOT, though that's partly bc of two really long losing streaks. Will update any adds or closing of positions.Longby redwingcoachUpdated 440
APPLE: Buy lower if this level breaks. Next target = 260.Apple is neutral on its 1D technical outlook (RSI = 45.352, MACD = -0.130, ADX = 33.865) as it is consolidating around the 1D MA50. The trend is a bearish one, correcting under LH and until they break, it will remain bearish. Much like the Channel Down corrections of 2023 and 2024, failure to cross above the top of the bearish pattern, should extend the selling to the 1D MA100 again, even the 1D MA200 if it fails. The 1D RSI of the prior tw fractals indicates that two main LH should be formed before the price recovers. This shows that we should take our time with AAPL and if the 1.5 Fib level breaks, buy on the 1D MA100 and the 1D MA200 for the long term. TP = 260.00 (the 2.5 Fibonacci level). See how our prior idea has worked out: ## If you like our free content follow our profile to get more daily ideas. ## ## Comments and likes are greatly appreciated. ##by InvestingScope8
NVDA: Wave 4NVDA appears to have completed 3 waves down, so looking for a retrace to 118-123 over the next week for wave 4, then a final plunge to $80 for wave 5by FiboTrader14415
$SMMT Stock Surges on Positive Lung Cancer Drug Trial ResultsShares of Summit Therapeutics (NASDAQ: NASDAQ:SMMT ) surged dramatically, soaring to an all-time high after the biotech firm reported promising results from its Phase 3 trial of ivonescimab, an experimental lung cancer treatment. The news sent the stock up by as much as 75.2% during intraday trading before settling at a 57.5% gain, marking a 54.77% increase by the close. These gains are driven by a powerful combination of strong clinical data and bullish market sentiment, positioning Summit as a rising star in the biotech space. Clinical Breakthrough: A Game-Changer for Lung Cancer Patients The Phase 3 trial, known as Harmoni-2, was conducted in China in collaboration with Summit's partner, Akeso. Ivonescimab was tested against Pembrolizumab (Keytruda), a standard-of-care treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with PD-L1-positive tumors. PD-L1 is a protein that helps cancer cells evade the immune system, making it a key target in immunotherapy. The results were striking: ivonescimab achieved a median progression-free survival (PFS) time of 11.14 months compared to 5.82 months for Keytruda, nearly doubling the time before the disease progressed or led to death. The drug reduced the risk of disease progression or death by 49% compared to other treatments, demonstrating a statistically significant improvement in the trial’s primary endpoint. This positive data marks a critical validation for Summit's approach, particularly as it outperformed Keytruda across all subgroups, including both low and high PD-L1 expressions and across squamous and non-squamous forms of the disease. This broad efficacy profile could make ivonescimab a highly versatile and sought-after option in the oncology space. haba CEO Robert Duggan on a 'Historic Moment Summit Therapeutics CEO Robert Duggan hailed the trial results as a "historic moment" for ivonescimab, calling it the beginning of a shift in the landscape of lung cancer treatment. Duggan stated, “We believe this is the beginning of a landscape shift for treatment options for patients living with cancer.” Summit plans to initiate a multi-regional study of ivonescimab in early 2025, further expanding its global reach. Ivonescimab’s success in both the Harmoni-2 trial and previous Harmoni-A trials positions it as a potential blockbuster in the making. Earlier trials showed ivonescimab’s efficacy when combined with chemotherapy, even in challenging cases where other monoclonal antibodies had failed. Technical Analysis: Caution Amidst the Euphoria On the technical front, NASDAQ:SMMT 's rapid ascent has pushed the stock into overbought territory, with a Relative Strength Index (RSI) of 81.44. Such a high RSI indicates that the stock is ripe for a potential pullback or consolidation as traders digest the news and early profit-takers emerge. The daily chart also shows a gap-up pattern, a phenomenon often filled in subsequent trading sessions as the market corrects its initial exuberance. While the upward momentum remains strong, traders and investors should be mindful of the possibility of a short-term correction, especially given the sharp run-up. This could offer a more attractive entry point for those looking to capitalize on Summit's long-term potential. The Road Ahead: Blockbuster Potential and Key Risks Summit’s ivonescimab could be on the path to becoming a key player in the cancer treatment market, potentially rivaling established therapies like Keytruda. The planned multi-regional trial in 2025 will be crucial in confirming ivonescimab’s efficacy and safety on a global scale. However, investors should also consider the inherent risks. Early-stage biotechs like Summit face significant hurdles, including regulatory scrutiny, competitive pressures, and the financial burden of advancing clinical trials. Any setbacks in the drug’s development, unexpected adverse events, or delays could impact the company’s stock performance. Conclusion: Summit Therapeutics ( NASDAQ:SMMT ) has captured the market’s attention with its impressive trial results for ivonescimab, setting the stage for what could be a transformative journey in lung cancer treatment. While technical indicators suggest caution in the short term, the long-term outlook for NASDAQ:SMMT remains compelling. With continued clinical success and a strategic approach to expansion, Summit is well-positioned to carve out a significant niche in the oncology market. Investors should keep a close watch on the company’s progress as it navigates the complexities of bringing a potentially groundbreaking cancer therapy to market. As Summit continues to build on this momentum, the stock could offer substantial upside for those willing to weather the inherent volatility of the biotech sector.Longby DEXWireNews3
Oracle (ORCL): Bullish Outlook Ahead of EarningsToday, we’re getting the earnings report on ORCL, and we’ve had to adjust our last analysis accordingly. We are now looking at a more bullish scenario after our previous bearish outlook was invalidated. If Oracle holds the desired level, we believe our current wave count is accurate. The count is pretty straightforward, and we think we’re now in the intra wave (ii) of the larger wave 3. This wave (ii) might touch the trend channel again, though it doesn’t necessarily have to. The channel seems accurate as waves ((i)), ((ii)), and ((iii)) are all tagging it. It would have been ideal if wave ((iv)) had touched it as well, but perfection is rare in markets. We’re focusing on the area between $133.43 and $129 to hold. We’re not setting any limit orders for ourselves just yet, as we want to see if our new count proves correct before making any moves.Longby freeguy_by_wmc2
NVDIA Is disaster just ahead of us?NVIDIA corporation (NVDA) is on a 3-month pull-back, the first it had on a 1M basis since September - October 2023. The latter was simply a mid-Bull consolidation phase within the wider picture of a Channel Up pattern that started almost 10 years ago. The price is pulling-back from the Channel's top (Higher Highs trend-line) and if the 1M MACD forms a Bearish Cross, we should be preparing for a cyclical correction within the pattern which in the previous two times (November 2021 and October 2018 tops) it corrected back to the 1M MA50 (blue trend-line) to form a bottom. The Nov 2021 top was formed exactly at the time of the 1M MACD Bearish Cross, while the October 2018 top was formed 10 months after. If this is a 3-year Cycle then in October or November (2024) we should really see the extent of the correction. If not then this might be another Mid-bull consolidation and we may have (roughly) another 10-12 months before this Cycle tops. What do you think it's going to be?? ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇by TradingShot33
Shopify (SHOP): Is It Just the Beginning?Shopify has been one of our best entries this year, and we remain very bullish on it. From a technical analysis perspective, it's hard to make a bearish case for this stock. We've even seen a change of structure after catching the bottom on SHOP. We've already taken some profits off the table and moved our stop loss to break even for the initial trade. We're now expecting this surge to continue, and as a result, we're planning to place another limit order on Shopify, aiming to buy more if the price moves into the $59.38-$54.59 area. We prefer to enter manually to avoid getting triggered by any sudden news events. If our analysis is correct and this is indeed Wave 2, we could see a really nice rally in the near future on Shopify, potentially breaking the $90 mark and moving even higher. Let's see what Shopify has in store for us next.Longby freeguy_by_wmc222
e.l.f. Beauty (ELF): Oversold and Ready for a ReboundIt has been quite some time since we last took a look at e.l.f. Beauty, and our previous conclusion was that we could be seeing some more selling pressure. We were right about it; after a brief relief pump, the stock sold off by more than 45%. In the end, our prediction about ELF being due for a sell-off was correct, and we are now back in the targeted area. Although we haven't touched the HVN POC yet, the situation looks both promising and concerning at the same time. Additionally, the RSI is oversold for the first time since October 2023. Given the current market conditions and the prevailing uncertainty, we are not planning to go long on ELF at this time. However, it does appear ready to either fall a bit more or take off. We will continue to monitor it closely and have already set alerts. If we see an upward push, we might consider entering on a retest, but for now, we're staying on the sidelines. We hope this update has been helpful to you 🔥Longby freeguy_by_wmc2
Sunnova 30% upsideSunnova has broken out of a 4-year downward trend, marking a significant move to confirm the breakout. The next major resistance level is at $13.70, presenting a potential 30% upside until reaching that point. Longby AZ_Cap1
ATT PredictionPossible ALT BAT. This is highly predicted and possibly wrong but posting to see how it plays out versus my initial thesis. AB Point around .5 Fib Potential C point fulfilled around 114 fib and fills a gap. I don't believe in coincidencesby HotsauceShoTYME0
thinkin about INTELThinkin those natty disasters really putting intel in a bind, too many red lights, too many wars, too much covid and ( other things you know what i mean ) Plan with intel, thinkin IF there are any wars Natty disasters or anything, short. thinkin IF all the traffic lights are green, and world peace is accomplished, hold. Thinkin aadi is still a baadiby LetsGetRichBabyyyyyyy116
ChargePoint bottomed outChargePoint had a rough earnings season, no doubt. However, its improvements in profitability show promise, suggesting it could approach break-even within the next 1-2 years. Given its unique business model—especially compared to other EV charging infrastructure companies—ChargePoint's significant and growing software segment stands out. Could we soon see a shift in valuation that factors in this blend of software and infrastructure, rather than just viewing it as a pure infrastructure play? Price target $2.7 if it continues on its current pattern and trend, and some slight shift in the market sentiment on the stock. CHPT is trade at 1.0x PS ratio, vs EVGO trading at 6.5x......Longby AZ_Cap776
Technical Analysis of Super Micro Computer Inc (SMCI)Upon analyzing the stock SMCI , we observe a significant turning point starting in 2022, following a long period of sideways movement where the stock struggled to break above the $40 level. After this prolonged sideways phase, the stock broke out with a clear upward trend, highlighted by the ascending trendline (green), characterized by higher highs and higher lows. Following a year of gains, the stock entered a consolidation phase but then broke out again to the upside with strength, accompanied by a substantial increase in volume. After reaching a peak in March 2024, the stock began a downward phase that is still ongoing. Potential long entry points, where the stock might bounce or change trend direction, are found in the following two support areas: Support area S1; The POC 1 area. If the stock begins to rally again, it will be crucial to monitor its behavior as it approaches the descending trendline (green), which could serve as a more conservative initial target. More ambitious targets are POC 2 and resistance R1, both within a price range of $900 to $1,000.by Giovanni_Bandini0
Various winners for SeptemberVarious winners for September. A look at some assets rising.by TradingviewM0
Tesla made second backtest on Trumpet ….NASDAQ:TSLA Tesla went above violett Trumpet pattern in June but failed to stay above early August. Last week we went above violett down trend but stopped Friday after heavy selling at the line - Today looks like backtest was successful!?! If this time we stay above, much higher prices are guaranteed (!) Longby Rolixc6
TSLA Short IdeaTSLA had another big fakeout above the major trendline from 2021 again last week and that sets the stage for a continued drop if it can't quickly reclaim. We also have a shorter term uptrend that as well that may lead to a flush below. I think this is a good spot to enter puts and target $200 and potentially even lower with a stop back above 220-222.Shortby AdvancedPlays116
$81.73 buy BiduBidu is the Google of China, currently trading at a P/E ratio of just over 10. They are also at the forefront of self driving technology, rapidly expanding in China, their technology is far more advanced than Tesla’s Share price is at multi year lows and as can be seen on the chart at multi year support levels. I expect considerable upside in the coming months by RIckAshby1